MedDataX Logo

Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano (IN.ON.D.)

NCT ID: NCT06180005

Last Updated: 2024-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-06

Study Completion Date

2039-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

According to an analysis by Memorial Sloan Kettering Cancer Center patients who receive a target therapy having an oncogenic driver mutation live longer than those who do not receive it. In addition to that, therapies guided by analysis on mutations identified in ct-DNA had a favorable impact, allowing longer survival. All this suggests that the presence of a therapeutically targetable oncogene (oncogene addicted) allows target therapy, resulting in a longer life expectancy. The main objective of this study is to evaluate the frequency of patients with oncogene addiction in a consecutive series of patients with NSCLC afferent to the CRO. Oncogene addiction is defined as being carriers of one of the mutations among EGFR, ALK, RET, KRAS, BRAF, Her2, ROS1, MET or other mutations that become therapeutic targets under investigation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohor

NCT06076005

Lung Cancer Stage IV
RECRUITING

Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

NCT01580982

Lung Neoplasms
RECRUITING

Analysis of Plasma Tumor DNA in Lung Cancer Patients

NCT01930474

Non Small Cell Lung Cancer Patients
UNKNOWN

Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer

NCT00923884

Carcinoma, Non-Small Cell Lung Carcinoma, Small-Cell Lung
COMPLETED

Radiomics and Radiogenomics of Non-small Cell Lung Cancer

NCT06331975

Non Small Cell Lung Cancer
COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

According to an analysis by Memorial Sloan Kettering Cancer Center patients who receive a target therapy having an oncogenic driver mutation live longer than those who do not receive it. In addition to that, therapies guided by analysis on mutations identified in ct-DNA had a favorable impact, allowing longer survival. All this suggests that the presence of a therapeutically targetable oncogene (oncogene addicted) allows target therapy, resulting in a longer life expectancy. The main objective of this study is to evaluate the frequency of patients with oncogene addiction in a consecutive series of patients with NSCLC afferent to the CRO. Oncogene addiction is defined as being carriers of one of the mutations among EGFR, ALK, RET, KRAS, BRAF, Her2, ROS1, MET or other mutations that become therapeutic targets under investigation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* First visit or first admission to CRO occurred in the period from September 2023 to September 2028
* Diagnosis of NSCLC any stage

Exclusion Criteria

\- Diagnosis of tumor not of certain lung origin (uncertain origin)
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centro di Riferimento Oncologico - Aviano

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alessandro Del Conte, MD

Role: PRINCIPAL_INVESTIGATOR

Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS

Alessandra Bearz, MD

Role: STUDY_DIRECTOR

Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS

Aviano, Pordenone, Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alessandro Del Conte, MD

Role: CONTACT

[email protected]
0434 399464

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alessandro Del Conte, MD

Role: primary

[email protected]
0434 399464

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRO-2023-38

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center
NCT04493827 COMPLETED
The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer
NCT02380196 COMPLETED
Molecular and Genetic Analysis of Lung Cancer
NCT03029325 RECRUITING
Genetic Epidemiology of Lung Cancer
NCT00341835 COMPLETED
Comprehensive Demographics and Clinical Profile of NSCLC Patients
NCT06725537 NOT_YET_RECRUITING
DNA Analysis of Blood and Tissue from Patients with Lung Cancer
NCT00471978 RECRUITING
The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients
NCT07188480 RECRUITING NA
Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer
NCT01052818 UNKNOWN
Metabolomics Predict Therapy Response
NCT03736993 COMPLETED NA
Detection of Genetic Markers of Lung Cancer
NCT00280202 RECRUITING
A Prognosis and Predicting Genetic Study of Lung Cancer
NCT03234179 NOT_YET_RECRUITING
Characteristics of Sexual Dysfunction in Patients With Lung Cancer
NCT06018376 COMPLETED
Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer
NCT07288632 RECRUITING
Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients
NCT05619562 COMPLETED
Non-small Cell Lung Cancer and Quality of Life
NCT00818402 COMPLETED
Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer
NCT04266691 COMPLETED
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
NCT01414595 COMPLETED
Impact of Lung Cancer Diagnosis on Relatives' Understanding of Genetic Risk and Receptivity to Quit Smoking
NCT00341341 COMPLETED
Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies
NCT05818020 COMPLETED
A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer
NCT05250817 COMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications
NCT01023828 COMPLETED
Multiomics Tumor Evolution Model of NSCLC
NCT05352035 RECRUITING
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
NCT05382052 ACTIVE_NOT_RECRUITING
Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation
NCT04137718 UNKNOWN
Study of Tumor Samples From Patients With Lung Cancer
NCT00900328 COMPLETED